Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer – OncLive
OncLive |
Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer
OncLive The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma (mUC), but simply changing the way quality of life (QoL) is monitored could provide dramatic improvements in … |
